Quick Search  in all journalsin this journalin this issue Journals Home Drugs of Today Issues Drugs of Today Policies & Guidelines Subscribe Permissions My Profile Contact Us Shopping Cart Purchase History

	Drugs of Today		Register or sign in
	Drugs Today 2000, 36(6): 383 ISSN 1699-3993 Copyright 2000 Clarivate CCC: 1699-3993 DOI: 10.1358/dot.2000.36.6.584259
	Leflunomide: Efficacy and safety in clinical trials for the treatment of rheumatoid arthritis Schiff, M.H., Strand, V., Oed, C., Loew-Friedrich, I.
	Leflunomide is a new disease modifying antirheumatic drug (DMARD) that inhibits lymphocyte proliferation by blocking dihydroorotate dehydrogenase (DHODH), the enzyme critical for the production of pyrimidine necessary for DNA synthesis. Through this mode of action, leflunomide inhibits the lymphocyte proliferation associated with the clonal expansion of T cells in rheumatoid arthritis (RA). In clinical trials, leflunomide was superior to placebo and comparable to sulfasalazine and methotrexate for improving both the signs and symptoms of RA. Leflunomide was also superior to placebo and sulfasalazine and comparable to methotrexate in overall improvement of physical function. Leflunomide was equivalent to methotrexate and sulfasalazine in retarding disease progression measured radiographically. Due to its unique mode of action in the treatment of RA, leflunomide shows value in combination therapy with methotrexate for patients refractory to methotrexate alone. The most common adverse reactions associated with leflunomide therapy include gastrointestinal symptoms, allergic reactions, reversible alopecia and elevated liver enzymes. Adverse events were generally mild to moderate, and resolved without complication. The results of phase II and phase III clinical trials indicate that leflunomide is a safe and efficacious drug for the treatment of RA. Full Text: HTML, PDF

	© Clarivate. All rights reserved.
	Copyright Notice	Terms of Use	Privacy Statement	Cookie Policy